alexa Evaluation of Bioequivalence and Cardio-Hepatic Safety of a Single Dose of Fixed Dose Combination of Artemether and Lumefantrine | OMICS International
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Evaluation of Bioequivalence and Cardio-Hepatic Safety of a Single Dose of Fixed Dose Combination of Artemether and Lumefantrine

Suhas Sahebrao Khandave1*, Santosh Shrikrishna Joshi2, Satish Vitthal Sawant1 and Shahoo Vasant Onkar1

1Accutest Research Laboratories Limited, A-31, TTC Industrial Area, Khairne MIDC, Navi Mumbai- 400709, Maharashtra, India

2Sequel Pharmchem Pvt Limited, Factory: N-46 MIDC, Anand Nagar, Ambernath, Thane- 421504, Maharashtra, India

*Corresponding Author:
Dr. Suhas Sahebrao Khandave
Accutest Research Laboratories Limited
A-31, TTC Industrial Area
Khairne MIDC, Navi Mumbai- 400709
Maharashtra, India
Tel: 91-22-27780718/19/20
Fax: 91-22-27780721
E-mail: [email protected]

Received Date: June 07, 2010; Accepted Date: July 01, 2010; Published Date: July 01, 2010

Citation: Khandave SS, Joshi SS, Sawant SV, Onkar SV (2010) Evaluation of Bioequivalence and Cardio-Hepatic Safety of a Single Dose of Fixed Dose Combination of Artemether and Lumefantrine. J Bioequiv Availab 2: 081-085. doi: 10.4172/jbb.1000036

Copyright: © 2010 Khandave SS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background and objective: The existing fixed-dose combination, Coartem® (artemether 20 mg and lumefantrine 80 mg) requires 4 tablets per dose and a total of 24 tablets for the six-dose regimen for the treatment of uncomplicated P. falciparum malaria compromising the patient compliance. Also, the cardiotoxicity due to lumefantrine because of its structural similarity with halofantrine remains a matter of debate in therapeutics. To enhance the patient compliance, the fixed-dose combination of artemether/lumefantrine (80/480 mg) is formulated by Sequel Pharmachem Pvt. Ltd. India. In the present study, this fixed dose combination (test product) was evaluated for its bioequivalence to the reference product, Coartem® 20/120 mg (artemether 20 mg and lumefantrine 120 mg) of Novartis Pharma Ltd. with assessment of cardio-hepatic safety. Methods: A randomized, open label, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study with comparative safety evaluation was conducted on 72 healthy Indian human subjects under a fed condition. Quantification of artemether, dihydroartemisinin, and lumefantrine was done by a validated LC-MS/ MS method. For bioequivalence, AUC0-240, AUC0-inf and Cmax for artemether and lumefantrine were considered. Safety assessment was done by monitoring vital signs, QTc interval, serum ALT and AST values before and after treatment. Max QTc, baseline-corrected QTcmax, AST and ALT values were considered for statistical comparison between the two treatments. Drug plasma concentrations estimated at identical time points with the ECG recordings were correlated with ECG parameters. Results: The test product was bioequivalent to the reference product as per the standard bioequivalence criteria. There was no clinically significant difference between the two treatments for all the safety parameters. No significant observation suggestive of cardiotoxicity and hepatotoxicity was noted in this study. Conclusion: The test product can be used as a therapeutic option with likely better patient compliance in the treatment of uncomplicated P. falciparum malaria.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version